| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;107:1183.)
© 2003 American Heart Association, Inc.
Basic Science Reports |
From the Laboratory of the Institute of Molecular Cardiobiology (N.S., M.M., A.O., M.A., B.O., E.M.), Johns Hopkins University, Baltimore, Md; Cardiovascular Sciences (S.-H.J., R.-P.X.), Gerontology Research Center, National Institute on Aging, National Institute of Health, Baltimore, Md; and the Experimental Research Laboratory (Y.G., R.B.), Division of Cardiology, University of Louisville and the Jewish Heart and Lung Institute, Louisville, Ky.
Correspondence to Eduardo Marbán, MD, PhD, Institute of Molecular Cardiobiology, Johns Hopkins University, 720 Rutland Ave/Ross 844, Baltimore, MD 21205. E-mail marban{at}jhmi.edu
Background MCC-134 (1-[4-(H-imidazol-1-yl)benzoyl]-N-methylcyclobutane-carbothioamide), a newly developed analog of aprikalim, opens surface smooth muscletype ATP-sensitive potassium (KATP) channels but inhibits pancreatic KATP channels. However, the effects of MCC-134 on cardiac surface KATP channels and mitochondrial KATP (mitoKATP) channels are unknown. A mixed agonist/blocker with differential effects on the two channel types would help to clarify the role of KATP channels in cardioprotection.
Methods and Results To index mitoKATP channels, we measured mitochondrial flavoprotein fluorescence in rabbit ventricular myocytes. MCC-134 alone had little effect on basal flavoprotein fluorescence. However, MCC-134 inhibited diazoxide-induced flavoprotein oxidation in a dose-dependent manner (EC50=27 µmol/L). When ATP was included in the pipette solution, MCC-134 slowly activated surface KATP currents with some delay (>10 minutes). These results indicate that MCC-134 is a mitoKATP channel inhibitor and a surface KATP channel opener in native cardiac cells. In cell-pelleting ischemia assays, coapplication of MCC-134 with diazoxide abolished the cardioprotective effect of diazoxide, whereas MCC-134 alone did not alter cell death. These results were reproducible in both rabbit and mouse myocytes. MCC-134 also attenuated the effect of ischemic preconditioning against myocardial infarction in mice, consistent with the results of cell-pelleting ischemia assays.
Conclusions A single drug, MCC-134, opens surface KATP channels but blocks mitoKATP channels; the fact that this drug inhibits preconditioning reaffirms the primacy of mitoKATP rather than surface KATP, channels in the mechanism of cardioprotection.
Key Words: ischemia potassium myocardial infarction
This article has been cited by other articles:
![]() |
J.-S. Bian, Q. C. Yong, T.-T. Pan, Z.-N. Feng, M. Y. Ali, S. Zhou, and P. K. Moore Role of Hydrogen Sulfide in the Cardioprotection Caused by Ischemic Preconditioning in the Rat Heart and Cardiac Myocytes J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 670 - 678. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Sato, A. D. T. Costa, T. Saito, T. Ogura, H. Ishida, K. D. Garlid, and H. Nakaya Bepridil, an Antiarrhythmic Drug, Opens Mitochondrial KATP Channels, Blocks Sarcolemmal KATP Channels, and Confers Cardioprotection J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 182 - 188. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Turner, K. Fujimoto, A. Suzuki, A. Stadnicka, Z. J. Bosnjak, and W.-M. Kwok The Interaction of Isoflurane and Protein Kinase C-Activators on Sarcolemmal KATP Channels Anesth. Analg., June 1, 2005; 100(6): 1680 - 1686. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kimura, G.-X. Zhang, A. Nishiyama, T. Shokoji, L. Yao, Y.-Y. Fan, M. Rahman, T. Suzuki, H. Maeta, and Y. Abe Role of NAD(P)H Oxidase- and Mitochondria-Derived Reactive Oxygen Species in Cardioprotection of Ischemic Reperfusion Injury by Angiotensin II Hypertension, May 1, 2005; 45(5): 860 - 866. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Pepe, O. W.V van den Brink, E. G Lakatta, and R.-P. Xiao Cross-talk of opioid peptide receptor and {beta}-adrenergic receptor signalling in the heart Cardiovasc Res, August 15, 2004; 63(3): 414 - 422. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Diaz, C. Zobel, H. Cheol Cho, M. Batthish, A. Hinek, P. H. Backx, and G. J. Wilson Selective Inhibition of Inward Rectifier K+ Channels (Kir2.1 or Kir2.2) Abolishes Protection by Ischemic Preconditioning in Rabbit Ventricular Cardiomyocytes Circ. Res., August 6, 2004; 95(3): 325 - 332. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. O'Rourke Evidence for Mitochondrial K+ Channels and Their Role in Cardioprotection Circ. Res., March 5, 2004; 94(4): 420 - 432. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Zaugg, E. Lucchinetti, M. Uecker, T. Pasch, and M. C. Schaub Anaesthetics and cardiac preconditioning. Part I. Signalling and cytoprotective mechanisms Br. J. Anaesth., October 1, 2003; 91(4): 551 - 565. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Gross and J. N. Peart KATP channels and myocardial preconditioning: an update Am J Physiol Heart Circ Physiol, August 7, 2003; 285(3): H921 - H930. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |